DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Planchard D, Mazieres J, Riely GJ et al.
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
J Clin Oncol 2013;
31 (Suppl. 01) Abstr 8009
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.